Merck & Co., Inc. Launches SAFLUTAN(R) (tafluprost) in International Markets

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today. SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2a for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma and ocular hypertension. SAFLUTAN is in Phase III in the U.S.